Madhavbaug, brand of NSE listed Vaidya Sane Ayurved Laboratories Ltd, a specialist in treating and reversing critical cardiac related ailment is all set to enter the next phase of growth through both organic and inorganic route.
Addressing the shareholders at the 23rd Annual General Meeting of the company and the first after listing of its shares on NSE in February 2022, Dr Rohit Sane, Founder, Managing Director and CEO of Madhavbaug explained in detail company’s strategy to promote Ayurveda among the masses through aggressive use of technology and collaboration with insurance companies and financial institutions to fund patients treatment expenses. The aim is to increase the reach of Ayurveda to every nook and corner of India and make Ayurveda treatment affordable to a vast majority of people in India.
Madhavbaug, has already inked an agreement with India’s leading insurer SBI General Insurance Company Ltd to provide policy holders direct cashless treatment facility at Madhavbaug’s hospitals. Additionally, the company is in various stages of negotiation with other insurers for extending similar cashless treatment facilities for their patrons as well.
“We are working towards getting empaneled with various insurance companies to provide access to Madhavbaug’s comprehensive set of Ayurvedic treatments and wellness therapies to its policyholders, and other stakeholders. We are also in the process of tying up with corporates to provide our state of the art healthcare services to their employees. To make our treatment universal and affordable to even the poorest needful section of the society, we are collaborating with various financial institutions for funding the treatment cost.
Under this plan, patients will have the flexibility to repay the principal amount through EMI whereas the interest component will be borne by Madhavbaug,” said Dr Rohit Sane.
By the end of 2025, Madhavbaug has envisaged to enroll 2 Lakhs patients per annum and increase the total number of health care centres to 600 as compared to 80-90k patients per annum with 270 care centres currently.
In FY 22, Madhavbaug reported 785 per cent growth in its profit after tax (PAT) at Rs 3.46 crore as compared to Rs 39.2 lakhs in FY21. During the same period, the company’s gross revenue increased from Rs 52.37 crore to Rs 75.04 crore.
Dr Sane also highlighted inorganic growth as part of the company’s key strategy going forward. “Madhavbaug has identified current market scenarios and business requirement necessitates inorganic growth for the company. Acquisitions of stake in companies with wide spread distribution channels; call centres, food and medicine manufacturers etc. can be considered as key to such growth,” he added.
Ayurveda is witnessing resurgence in India as people are approaching the ancient healthcare science as a way of life as opposed to the earlier notion of Ayurveda as an alternative area of medicine.
About us: With more than a decade experience in preventive cardiology, Madhavbaug has a strong track record of patients who have obtained relief from life threatening diseases with Madhavbaug’s treatments. Founded in 2006 with a vision to reduce the mortality and morbidity due to heart disease and lifestyle disorders, Madhavbaug has established a strong foothold in non-invasive cardiac care with 274 clinics and 2 hospitals.